siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma

Nucleic Acids Res. 2008 Jan;36(1):e2. doi: 10.1093/nar/gkm1094. Epub 2007 Dec 13.

Abstract

Delivery is a very important concern for therapeutic applications of siRNA. In this study, we have used chitosan-coated poly(isobutylcyanoacrylate) nanoparticles to deliver siRNA with a complementary sequence to the fusion oncogene ret/PTC1. By screening the mRNA junction we have selected a potent siRNA sequence able to inhibit this oncogene in a model of Papillary Thyroid Carcinoma cells. This siRNA sequence has then been validated by a shRNA approach using the same sequence. Furthermore, the high ret/PTC1 inhibition has triggered a phenotypic reversion of the transformed cells. We have designed well-defined chitosan decorated nanoparticles and succeeded to reduce their size. They have allowed to protect ret/PTC1 siRNA from in vivo degradation and leading to significant tumour growth inhibition after intratumoral administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adsorption
  • Animals
  • Bucrylate / chemistry
  • Carcinoma, Papillary / therapy*
  • Cell Line, Transformed
  • Chitosan / chemistry
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Nude
  • NIH 3T3 Cells
  • Nanoparticles / chemistry*
  • Oncogene Proteins, Fusion / antagonists & inhibitors*
  • Oncogene Proteins, Fusion / genetics
  • Plasmids / genetics
  • Polymers / chemistry
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Protein-Tyrosine Kinases / genetics
  • RNA Interference*
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / chemistry
  • Sequence Analysis, RNA
  • Thyroid Neoplasms / therapy*

Substances

  • Oncogene Proteins, Fusion
  • Polymers
  • RNA, Small Interfering
  • Bucrylate
  • Chitosan
  • Protein-Tyrosine Kinases
  • ret-PTC fusion oncoproteins, human